Legal Representation
Attorney
Albert P. Halluin
USPTO Deadlines
Application History
29 eventsDate | Code | Type | Description |
---|---|---|---|
Jan 11, 2010 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
Jan 11, 2010 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED |
Jun 30, 2009 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
Jun 30, 2009 | EX5G | S | EXTENSION 5 GRANTED |
Jun 8, 2009 | EEXT | I | TEAS EXTENSION RECEIVED |
Jun 8, 2009 | EXT5 | S | EXTENSION 5 FILED |
Dec 1, 2008 | EEXT | I | TEAS EXTENSION RECEIVED |
Dec 1, 2008 | EXT4 | S | EXTENSION 4 FILED |
Dec 1, 2008 | EX4G | S | EXTENSION 4 GRANTED |
Jun 4, 2008 | EEXT | I | TEAS EXTENSION RECEIVED |
Jun 4, 2008 | EXT3 | S | EXTENSION 3 FILED |
Jun 4, 2008 | EX3G | S | EXTENSION 3 GRANTED |
Dec 3, 2007 | EEXT | I | TEAS EXTENSION RECEIVED |
Dec 3, 2007 | EXT2 | S | EXTENSION 2 FILED |
Dec 3, 2007 | EX2G | S | EXTENSION 2 GRANTED |
Jun 5, 2007 | EEXT | I | TEAS EXTENSION RECEIVED |
Jun 5, 2007 | EXT1 | S | EXTENSION 1 FILED |
Jun 5, 2007 | EX1G | S | EXTENSION 1 GRANTED |
Dec 12, 2006 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT |
Sep 19, 2006 | PUBO | A | PUBLISHED FOR OPPOSITION |
Aug 30, 2006 | NPUB | O | NOTICE OF PUBLICATION |
Jul 27, 2006 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED |
Jul 21, 2006 | ALIE | A | ASSIGNED TO LIE |
Jul 17, 2006 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
Jul 13, 2006 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
Jul 13, 2006 | GNEA | F | EXAMINERS AMENDMENT E-MAILED |
Jul 13, 2006 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
Jun 29, 2006 | DOCK | D | ASSIGNED TO EXAMINER |
Jan 18, 2006 | NWAP | I | NEW APPLICATION ENTERED IN TRAM |
Detailed Classifications
Class 005
medical diagnostic and therapeutic preparations, all for administration via diverse routes of administration including through the respiratory airways, and, medical devices for administering the pharmaceuticals, sold filled, the preparations including nucleotides, proteins and organic molecules for medical use, including macromolecules such as anti-sense oligonucleotides and enzymes and small and inorganic molecules for treatment of human and non-human animal respiratory, central nervous system, neoplastic, endocrine, immune and cardiovascular ailments, including bronchoconstriction, difficult breathing, impeded and obstructed lung airways, allergy(ies) and/or inflammation, which in some cases are adenosine receptor associated symptoms; pharmaceutical preparations for testing, and preventing and therapeutically treating respiratory, airway and pulmonary diseases and conditions, such as asthma, pulmonary vasconconstriction, inflammation, allergies, impeded respiration, acute respiratory disease syndrome (ARDS), renal damage and failure, ischemia resulting from the administration of certain drugs, including adenosine and other drugs for, for example, treating supra ventricular tachycardia (SVT), adenosine stress tests, infantile respiratory distress syndrome (infantile RDS), pain, cystic fibrosis, allergic rhinitis, allergic bronchitis, pulmonary hypertension, pulmonary vasconcontriction, emphysema, chronic obstructive pulmonary disease (COPD), as well as cancers including leukemias, lymphomas, carcinomas, and the like, eg colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, etc, as well as metastatic cancers, eg, cancers which metastasized to the lung(s), breast, liver and prostate
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"PHARMACEUTICALS"
USPTO Documents
Loading USPTO documents...